Penumbra Inc Stock
Pros and Cons of Penumbra Inc in the next few years
Pros
?
S********** s********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
C******** o* t** e**********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Penumbra Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Penumbra Inc | 2.560% | 3.277% | 10.108% | 10.200% | 16.505% | 29.755% | 67.532% |
| Icu Medical Inc. | 0.000% | 3.306% | 1.626% | -20.886% | -14.966% | -14.966% | -22.360% |
| Bio-Rad Labs Inc. A | 1.740% | -1.966% | -4.673% | -17.189% | -14.263% | -31.823% | -41.201% |
| Neogen Corp. | -2.480% | 13.592% | 4.464% | -51.250% | -51.250% | - | - |
News
Penumbra (PEN) Q2 Revenue Jumps 13%
Penumbra (NYSE:PEN), a medical device innovator focused on clot removal and vascular care, reported its second quarter 2025 results on July 29, 2025. The company delivered $339.5 million in GAAP
